{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:59:03Z","timestamp":1773917943140,"version":"3.50.1"},"reference-count":193,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017117","name":"Denali Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ymgme.2025.109248","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:14:36Z","timestamp":1759299276000},"page":"109248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unmet needs in the treatment and care of somatic manifestations in mucopolysaccharidosis type II: A targeted literature review"],"prefix":"10.1016","volume":"146","author":[{"given":"Barbara K.","family":"Burton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fertek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M.P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Magner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Ezg\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moeenaldeen","family":"AlSayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109248_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2025.109248_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/ijns10040071","article-title":"A systematic literature review on the global status of newborn screening for mucopolysaccharidosis II","volume":"10","author":"Ayodele","year":"2024","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2025.109248_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-018-0816-4","article-title":"Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan","volume":"13","author":"Chuang","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0025","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ymgme.2021.11.234","article-title":"Current status of newborn screening for lysosomal diseases in Japan: importance of novel therapies for central nervous system manifestation in MPS II, and importance of family screening of Fabry disease after newborn screening","volume":"135","author":"Okuyama","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0030","doi-asserted-by":"crossref","first-page":"9979","DOI":"10.3390\/ijms23179979","article-title":"Updated confirmatory diagnosis for mucopolysaccharidoses in Taiwanese infants and the application of gene variants","volume":"23","author":"Chuang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.a.34415","article-title":"Mucopolysaccharidosis type II in females and response to enzyme replacement therapy","volume":"158A","author":"Jurecka","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2025.109248_bb0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome)","volume":"5","author":"Stapleton","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2025.109248_bb0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1750-1172-8-92","article-title":"Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study","volume":"8","author":"Guill\u00e9n-Navarro","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40246-024-00701-w","article-title":"Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants","volume":"18","author":"Zanetti","year":"2024","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.ymgme.2025.109248_bb0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.14712\/fb2016062020082","article-title":"X-chromosome inactivation analysis in different cell types and induced pluripotent stem cells elucidates the disease mechanism in a rare case of Mucopolysaccharidosis type II in a female","volume":"62","author":"Reboun","year":"2016","journal-title":"Folia Biol. (Praha)"},{"key":"10.1016\/j.ymgme.2025.109248_bb0060","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.3390\/ijms22157888","article-title":"Differences in MPS I and MPS II disease manifestations","volume":"22","author":"Hampe","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0065","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/jcm9020396","article-title":"Brain pathology in mucopolysaccharidoses (MPS) patients with neurological forms","volume":"9","author":"Viana","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0070","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1093\/hmg\/ddy155","article-title":"The pathogenesis of lysosomal storage disorders: beyond the engorgement of lysosomes to abnormal development and neuroinflammation","volume":"27","author":"Fiorenza","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2025.109248_bb0075","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/biomedicines11061668","article-title":"Diagnosis and management of mucopolysaccharidosis type II (Hunter syndrome) in Poland","volume":"11","author":"\u017buber","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymgme.2025.109248_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108576","article-title":"Genotype-phenotype findings in patients with mucopolysaccharidosis II from the Hunter outcome Survey","volume":"143","author":"Muenzer","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.012","article-title":"Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States","volume":"25","author":"Ream","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0090","series-title":"GeneReviews\u00ae, Seattle (WA)","article-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"2025"},{"key":"10.1016\/j.ymgme.2025.109248_bb0095","article-title":"Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: an analysis from the Hunter outcome Survey","volume":"37","author":"Lau","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13023-022-02396-5","article-title":"Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study","volume":"17","author":"Sestito","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0115","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II - a historical review based on data from the Hunter outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0125","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108507","article-title":"Causes of death in mucopolysaccharidoses","volume":"142","author":"Rintz","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0145","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/jcm12020480","article-title":"Airway findings in patients with Hunter syndrome treated with intravenous idursulfase","volume":"12","author":"De Vuyst","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/diagnostics11010016","article-title":"Aortic root dilatation in Taiwanese patients with mucopolysaccharidoses and the long-term effects of enzyme replacement therapy","volume":"11","author":"Lin","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2025.109248_bb0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment","volume":"33","author":"Giugliani","year":"2010","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0160","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0165","first-page":"27","article-title":"Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI","volume":"7","author":"Ahmed","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0170","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cge.12927","article-title":"Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II","volume":"91","author":"Dvorakova","year":"2017","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2025.109248_bb0175","article-title":"Elaprase history and global usage","author":"Pharmaceuticals","year":"2024","journal-title":"Intended for US healthcare professionals only"},{"key":"10.1016\/j.ymgme.2025.109248_bb0180","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40259-024-00675-0","article-title":"Targeting neurological aspects of mucopolysaccharidosis type II: enzyme replacement therapy and beyond","volume":"38","author":"Zanetti","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.ymgme.2025.109248_bb0185","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109248_bb0190","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.pedneo.2022.10.001","article-title":"Current and new therapies for mucopolysaccharidoses","volume":"64","author":"Penon-Portmann","year":"2023","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0195","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2025.109248_bb0200","author":"US Food and Drug Administration"},{"key":"10.1016\/j.ymgme.2025.109248_bb0205","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2025.109248_bb0210","author":"GC Biopharma, About Hunterase"},{"key":"10.1016\/j.ymgme.2025.109248_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107709","article-title":"Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: final report of 5-year results from a Japanese open-label phase 1\/2 study","volume":"140","author":"Seo","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0220","author":"CANbridge Pharmaceuticals"},{"key":"10.1016\/j.ymgme.2025.109248_bb0225","author":"Biopharma"},{"key":"10.1016\/j.ymgme.2025.109248_bb0230","author":"Korea Biomedical Review"},{"key":"10.1016\/j.ymgme.2025.109248_bb0235","author":"Japanese Pharmaceuticals and Medical Devices Agency"},{"key":"10.1016\/j.ymgme.2025.109248_bb0240","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109248_bb0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0250","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0255","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ymgme.2014.08.009","article-title":"Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome","volume":"114","author":"Sohn","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0260","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0265","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-sulfatase fused with anti-hTfr antibody, pabinafusp alfa, for MPS-II: a phase 2 trial in Brazil","volume":"29","author":"Giugliani","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109248_bb0270","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/gim.2013.162","article-title":"A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy","volume":"16","author":"Giugliani","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0290","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","article-title":"Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the Hunter outcome Survey (HOS)","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","article-title":"Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0300","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13023-020-01382-z","article-title":"Critical clinical situations in adult patients with mucopolysaccharidoses (MPS)","volume":"15","author":"Stepien","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0305","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ymgme.2025.109248_bb0310","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5195\/jmla.2021.962","article-title":"PRISMA-S group, PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"109","author":"Rethlefsen","year":"2021","journal-title":"J. Med. Libr. Assoc."},{"key":"10.1016\/j.ymgme.2025.109248_bb0315","author":"Takeda Pharmaceuticals"},{"key":"10.1016\/j.ymgme.2025.109248_bb0320","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0325","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/GIM.0b013e3181f6e74d","article-title":"Hunter outcome Survey Investigators, importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter outcome Survey","volume":"12","author":"Mendelsohn","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0330","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Hunter syndrome European expert council, Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0335","author":"Thomas"},{"key":"10.1016\/j.ymgme.2025.109248_bb0340","author":"Gadepalli"},{"key":"10.1016\/j.ymgme.2025.109248_bb0345","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00431-013-1967-x","article-title":"Hunter outcome Survey Investigators, development of a mnemonic screening tool for identifying subjects with Hunter syndrome","volume":"172","author":"Cohn","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0350","first-page":"23","article-title":"Newborn screening for Hunter disease: a small-scale feasibility study","volume":"14","author":"Ruijter","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0355","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/ijns8040055","article-title":"Addition of MPS-II to the recommended uniform screening panel in the United States","volume":"8","author":"Millington","year":"2022","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2025.109248_bb0360","author":"Resources"},{"key":"10.1016\/j.ymgme.2025.109248_bb0365","author":"Australian Government Department of Health and Aged Care"},{"key":"10.1016\/j.ymgme.2025.109248_bb0370","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ijns8020025","article-title":"A new approach to objectively evaluate inherited metabolic diseases for inclusion on newborn screening programmes","volume":"8","author":"Burlina","year":"2022","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2025.109248_bb0375","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns8010020","article-title":"Application of a novel algorithm for expanding newborn screening for inherited metabolic disorders across Europe","volume":"8","author":"Jones","year":"2022","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2025.109248_bb0380","doi-asserted-by":"crossref","first-page":"67","DOI":"10.36469\/jheor.2022.36540","article-title":"Impact of the timing of enzyme replacement therapy initiation and cognitive impairment status on outcomes for patients with mucopolysaccharidosis II (MPS II) in the United States: a retrospective chart review","volume":"9","author":"Yee","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"key":"10.1016\/j.ymgme.2025.109248_bb0385","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0390","article-title":"Timing is everything: clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair","volume":"30","author":"Grant","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0395","article-title":"Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase-IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II","volume":"48","author":"Muenzer","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0400","first-page":"9","article-title":"Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: a case report","volume":"62","author":"Tomita","year":"2021","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0405","first-page":"99","article-title":"Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age","volume":"14","author":"Lampe","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0410","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0415","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up","volume":"101","author":"Tylki-Szymanska","year":"2012","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0420","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/ijms23094854","article-title":"Current and future treatment of mucopolysaccharidosis (MPS) type II: is brain-targeted stem cell gene therapy the solution for this devastating disorder?","volume":"23","author":"Horgan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0425","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0430","first-page":"62","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7 years follow-up","volume":"12","author":"Barth","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0435","article-title":"Real world long-term outcomes in patients with mucopolysaccharidosis type II: a retrospective cohort study","volume":"29","author":"Tomita","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0440","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2014.11.002","article-title":"Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation","volume":"114","author":"Tanjuakio","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0445","article-title":"Efficacy of early haematopoietic stem cell transplantation versus enzyme replacement therapy on neurological progression in severe Hunter syndrome: case report of siblings and literature review","volume":"32","author":"Sreekantam","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0450","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2025.109248_bb0455","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41436-020-0909-z","article-title":"ACMG therapeutics committee, treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"McBride","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0460","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/21678707.2013.738182","article-title":"Evaluation of idursulfase for the treatment of mucopolysaccharidosis II (Hunter syndrome)","volume":"1","author":"Scarpa","year":"2013","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2025.109248_bb0465","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1111\/cts.13652","article-title":"Dose selection for biological enzyme replacement therapy indicated for inborn errors of metabolism","volume":"16","author":"Hon","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0470","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ymgme.2007.03.003","article-title":"Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II","volume":"91","author":"Garcia","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0475","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2025.109248_bb0480","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2020.06.004","article-title":"Retrospective chart review of urinary glycosaminoglucan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses","volume":"130","author":"Jones","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0485","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","article-title":"Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"134A","author":"Swiedler","year":"2005","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2025.109248_bb0490","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0495","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0500","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2025.109248_bb0505","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0510","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymgme.2016.09.005","article-title":"Glycosaminoglycans detection methods: applications of mass spectrometry","volume":"120","author":"Kubaski","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0515","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0520","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.3390\/ijms21155449","article-title":"High-throughput liquid chromatography-tandem mass spectrometry quantification of glycosaminoglycans as biomarkers of mucopolysaccharidosis II","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0525","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2008.05.001","article-title":"Heparin cofactor II-thrombin complex: a biomarker of MPS disease","volume":"94","author":"Randall","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0530","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10545-011-9369-6","article-title":"Longitudinal observations of serum heparin cofactor II-thrombin complex in treated mucopolysaccharidosis I and II patients","volume":"35","author":"Clarke","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0535","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10545-010-9254-8","article-title":"Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases","volume":"34","author":"Langford-Smith","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0540","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymgme.2018.04.011","article-title":"Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis","volume":"125","author":"Khan","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0545","article-title":"Biomarkers in patients with mucopolysaccharidosis type II and IV","volume":"19","author":"Fujitsuka","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108535","article-title":"Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses","volume":"142","author":"Muenzer","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0555","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","article-title":"Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues","volume":"11","author":"Hendriksz","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0560","article-title":"Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: a case series","volume":"36","author":"Chan","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0565","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109248_bb0570","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.3390\/jcm11175158","article-title":"GOS steering committee, switching between enzyme replacement therapies and substrate reduction therapies in paitents with Gaucher disease: data from the Gaucher outcome Survey (GOS)","volume":"11","author":"Hughes","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0575","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"AFFIINITY group, switch from enzyme replacement therapy to oral chaperone migalastat for treating Fabry disease: real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2025.109248_bb0580","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ymgme.2012.08.013","article-title":"Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature","volume":"107","author":"Jurecka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0585","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome - an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0590","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0595","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12808","article-title":"Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapy","volume":"48","author":"Kampmann","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0600","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.3390\/ijms25168573","article-title":"Intravenous idursulfase for the treatment of mucopolysaccharidosis type II: a systematic literature review","volume":"25","author":"Al-Hertani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0605","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/diagnostics14171956","article-title":"Body height of MPS I and II patients after hematopoietic stem cell transplantation: the impact of dermatan sulphate","volume":"14","author":"Lipi\u0144ski","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2025.109248_bb0610","doi-asserted-by":"crossref","DOI":"10.1177\/2326409818779097","article-title":"Hematopoietic stem cell transplantation in mucopolysaccharidosis type II: a literature review and critical analysis","volume":"6","author":"Barth","year":"2018","journal-title":"J Inborn Errors Metab Screen."},{"key":"10.1016\/j.ymgme.2025.109248_bb0615","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2025.109248_bb0620","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/S1047951109003576","article-title":"The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses","volume":"19","author":"Fesslov\u00e1","year":"2009","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.ymgme.2025.109248_bb0625","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9444-z","article-title":"Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI","volume":"36","author":"Brands","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0630","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-014-0129-1","article-title":"Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years","volume":"9","author":"Tomanin","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0635","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ymgme.2013.11.001","article-title":"Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlated with arterial stiffness","volume":"111","author":"Wang","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0640","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00380-018-1242-1","article-title":"Aortic root dilatation in patients with mucopolysaccharidoses and the impact of enzyme replacement therapy","volume":"34","author":"Poswar","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ymgme.2025.109248_bb0645","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/ijms18030637","article-title":"The carotid intima-media thickness and arterial stiffness of pediatric mucopolysaccharidosis patients are increased compared to both pediatric and adult controls","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0650","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/ijms17122004","article-title":"Aortic root dilatation in mucopolysaccharidosis I-VII","volume":"17","author":"Bolourchi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0655","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-016-0425-z","article-title":"Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis","volume":"11","author":"Rutten","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0660","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0665","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.22774","article-title":"Characterization of pulmonary function impairments in patients with mucopolysaccharidsoses--changes with age and treatment","volume":"49","author":"Lin","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0670","first-page":"65","article-title":"Enzymatic replacement therapy for Hunter disease: up to 9 years experience with 17 patients","volume":"3","author":"Parini","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0675","first-page":"251","article-title":"Efficacy of enzyme replacement therapy on the range of motion of the upper and lower extremities in 16 polish patients with mucopolysaccharidosis type II: a long-term follow-up study","volume":"69","author":"Marucha","year":"2022","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0680","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ymgme.2013.03.001","article-title":"HOS natural history working group on behalf of HOS Investigators, the effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter outcome Survey (HOS)","volume":"109","author":"Jones","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0685","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10545-010-9215-2","article-title":"Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II","volume":"34","author":"Schulze-Frenking","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085074","article-title":"The effect of recombinant human iduronate-2-sulfatase (idursulfase) on growth in young patients with mucopolysaccharidosis type II","volume":"9","author":"\u017buber","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2025.109248_bb0695","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3346\/jkms.2014.29.2.254","article-title":"Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"29","author":"Cho","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0700","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/diagnostics10010005","article-title":"Diagnosis and management of carpal tunnel syndrome in children with mucopolysaccharidosis: a 10 year experience","volume":"10","author":"Dabaj","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2025.109248_bb0705","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13023-018-0937-9","article-title":"Early detection of median nerve compression by electroneurography can improve outcome in children with mucopolysaccharidoses","volume":"13","author":"Maincent","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2023.01.002","article-title":"Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery","volume":"58","author":"Malong","year":"2023","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ymgme.2025.109248_bb0715","first-page":"17","article-title":"Carpal tunnel syndrome in Fabry disease","volume":"2","author":"Ghali","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0720","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/jcm8091467","article-title":"Ophthalmological findings in mucopolysaccharidoses","volume":"8","author":"Tomatsu","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0725","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13816810.2021.1938141","article-title":"Expanding the phenotype of mucopolysaccharidosis type II retinopathy","volume":"42","author":"Kowalski","year":"2021","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.ymgme.2025.109248_bb0730","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/ICB.0000000000001537","article-title":"Progressive retinopathy in a patient with mucopolysaccharidosis type II undergoing enzyme replacement therapy: a case report","volume":"19","author":"Wouters","year":"2025","journal-title":"Retin. Cases Brief Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0735","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000500804","article-title":"Recovery of vision following enzyme replacement therapy in a patient with mucopolysaccharidosis type II, Hunter syndrome","volume":"10","author":"Yamanishi","year":"2019","journal-title":"Case Rep. Ophthalmol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0740","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0000000000003214","article-title":"Changes in corneal clouding over time in patients with mucopolysaccharidosis","volume":"42","author":"McGrath","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.ymgme.2025.109248_bb0745","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41409-022-01886-1","article-title":"Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type I-H: a retrospective study of 51 patients","volume":"58","author":"Gardin","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2025.109248_bb0750","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/diagnostics10080554","article-title":"Hearing loss in mucopolysaccharidoses: current knowledge and future directions","volume":"10","author":"Wolfberg","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2025.109248_bb0755","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1097\/MAO.0000000000002422","article-title":"Auditory characteristics in patients with mucopolysaccharidosis","volume":"40","author":"Ahn","year":"2019","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0760","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamaoto.2013.597","article-title":"Improvements in sensorineural hearing loss after cord blood transplant in patients with mucopolysaccharidosis","volume":"138","author":"Da Costa","year":"2012","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.ymgme.2025.109248_bb0765","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao0935","article-title":"Delivery of therapeutics to the inner ear: the challenge of the blood-labyrinth barrier","volume":"11","author":"Nyberg","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0770","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0775","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter outcome Survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0780","first-page":"2","article-title":"Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients","volume":"12","author":"Giugliani","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0785","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0790","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpeds.2022.05.008","article-title":"Effect of anti-iduronate 2-sulfatase antibodies in patients with mucopolysaccharidosis type II treated with enzyme replacement therapy","volume":"248","author":"Vollebregt","year":"2022","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0795","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.863667","article-title":"The inflammation in the cytopathology of patients with mucopolysaccharidoses - immunomodulatory drugs as an approach to therapy","volume":"13","author":"Wiesinger","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0800","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3390\/ijms21072515","article-title":"Pathogenesis of mucopolysaccharidoses, an update","volume":"21","author":"Fecarotta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0805","article-title":"Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey","volume":"2","author":"Link","year":"2010","journal-title":"Orthop. Rev. (Pavia)"},{"key":"10.1016\/j.ymgme.2025.109248_bb0810","article-title":"Inflammation and lipoperoxidation in mucopolysaccharidosis type II patients at diagnosis and post-hematopoietic stem cell transplantation","volume":"133\u2013134","author":"Delgado","year":"2024","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2025.109248_bb0815","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/ijms24010477","article-title":"Mucopolysaccharidoses: cellular consequences of glycosaminoglycans accumulation and potential targets","volume":"24","author":"Leal","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0820","first-page":"1608","article-title":"Oxidative and nitrative stress and pro-inflammatory cytokines in mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation","volume":"2016","author":"Jacques","year":"1862","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2025.109248_bb0825","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mrgentox.2018.08.013","article-title":"Hunter syndrome: long-term idursulfase treatment does not protect patients against DNA oxidation and cytogenetic damage","volume":"835","author":"Jacques","year":"2018","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen."},{"key":"10.1016\/j.ymgme.2025.109248_bb0830","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2011.02.016","article-title":"Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy","volume":"103","author":"Filippon","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0835","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mrgentox.2011.02.005","article-title":"DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; prospective effect of enzyme replacement therapy","volume":"721","author":"Filippon","year":"2011","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ymgme.2025.109248_bb0840","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/0310057X1604400612","article-title":"Anaesthetic implications of the changing management of patients with mucopolysaccharidosis","volume":"44","author":"Hack","year":"2016","journal-title":"Anaesth. Intensive Care"},{"key":"10.1016\/j.ymgme.2025.109248_bb0845","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/ijerph15102212","article-title":"The epidemiology of transition into adulthood of rare diseases patients: results from a population-based registry","volume":"15","author":"Mazzucato","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.ymgme.2025.109248_bb0850","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejim.2016.05.017","article-title":"Unique medical issues in adult patients with mucopolysaccharidoses","volume":"34","author":"Mitchell","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ymgme.2025.109248_bb0855","article-title":"Transition of patients with mucopolysaccharidosis from paediatric to adult care","volume":"21","author":"Lampe","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0860","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","article-title":"Health-related quality of life in patients with MPS II","volume":"24","author":"Needham","year":"2015","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2025.109248_bb0865","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/03007995.2024.2316213","article-title":"Humanistic burden of mucopolysaccharidoses: a systematic literature review","volume":"40","author":"Li","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ymgme.2025.109248_bb0870","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ymgme.2009.04.007","article-title":"Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses","volume":"97","author":"Burton","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109248_bb0875","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10545-008-0980-0","article-title":"Home treatment with elaprase and naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively","volume":"31","author":"Bagewadi","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0880","first-page":"311","article-title":"Review of the use of idursulfase in the treatment of mucopolysaccharidosis II","volume":"2","author":"Burrow","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.ymgme.2025.109248_bb0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ymgme.2025.109248_bb0890","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s13023-024-03432-2","article-title":"Study on the disease burden of patients with mucopolysaccharidosis type II in China","volume":"19","author":"Yuan","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0895","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/ijns6030073","article-title":"Newborn screening for mucopolysaccharidosis type II in Illinois: an update","volume":"6","author":"Burton","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2025.109248_bb0900","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2408402","article-title":"Mucopolysaccharidoses I and II: brief review of therapeutic options and supportive\/palliative therapies","volume":"2020","author":"Nan","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ymgme.2025.109248_bb0905","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years","volume":"154","author":"Guffon","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109248_bb0910","first-page":"33","article-title":"Management of life-threatening tracheal stenosis and tracheomalacia in patients with mucopolysaccharidoses","volume":"33","author":"Kampmann","year":"2017","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2025.109248_bb0915","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.4081\/cardiogenetics.2013.s1.e2","article-title":"Molecular basis, diagnosis and clinical management of mucopolysaccharidoses","volume":"3","author":"Parini","year":"2013","journal-title":"Cardiogenetics"},{"key":"10.1016\/j.ymgme.2025.109248_bb0920","author":"National"},{"key":"10.1016\/j.ymgme.2025.109248_bb0925","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1750-1172-8-101","article-title":"The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life","volume":"8","author":"Raluy-Callado","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0930","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/scd.12753","article-title":"Improving oral health-related quality of life for a child with hunter\u2019s syndrome: a case report and review of literature","volume":"43","author":"Elkhatib","year":"2023","journal-title":"Spec. Care Dentist."},{"key":"10.1016\/j.ymgme.2025.109248_bb0935","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","article-title":"Multidisciplinary management of Hunter syndrome","volume":"124","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2025.109248_bb0940","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s13023-022-02593-2","article-title":"Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study","volume":"17","author":"Guffon","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0945","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13023-016-0521-0","article-title":"Parents\u2019 experiences of living with, and caring for children, adolescents and young adults with mucopolysaccharidosis (MPS)","volume":"11","author":"Somanadhan","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0950","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/scs.13026","article-title":"Living through liminality? Situating the transitional experience of parents of children with mucopolysaccharidoses","volume":"36","author":"Somanadhan","year":"2022","journal-title":"Scand. J. Caring Sci."},{"key":"10.1016\/j.ymgme.2025.109248_bb0955","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13023-024-03112-1","article-title":"Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan","volume":"19","author":"Nakamura","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109248_bb0960","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0043-1778099","article-title":"The impact of pabinafusp alfa on the disease burden in hunter\u2019s syndrome: patient-reported outcomes","volume":"22","author":"Martins","year":"2024","journal-title":"J. Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2025.109248_bb0965","article-title":"An online survey of burden of illness in families with mucopolysaccharidosis type II children in the United States","volume":"21","author":"Conner","year":"2019","journal-title":"Mol Genet. Metab. Rep."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:52:48Z","timestamp":1773899568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225002392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":193,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1096719225002392"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109248","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs in the treatment and care of somatic manifestations in mucopolysaccharidosis type II: A targeted literature review","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109248"}}